Drug Discovery 플랫폼 시장 규모, 점유율, 산업 분석 : 약제 유형별, 최종 용도별, 용도별, 치료 영역별, 지역별, 전망 및 예측(2026-2033년)

The Global Drug Discovery Platforms Market is expected to reach USD 9,879.2 Million by 2033, growing at a CAGR of 14.8% during 2026 - 2033.

The Global Drug Discovery Platforms Market has evolved from conventional laboratory-based pharmacological research methods that relied heavily on trial-and-error experimentation, biochemical assays, and manual compound screening. Early drug discovery processes were labor-intensive, time-consuming, and characterized by high attrition rates. The emergence of bioinformatics, computational chemistry, high-throughput screening (HTS), genomics, proteomics, and cheminformatics transformed the market by enabling data-driven target identification and lead optimization. Over the past decade, advancements in artificial intelligence (AI), machine learning (ML), cloud computing, multi-omics analytics, and automation technologies have further revolutionized drug discovery platforms.

Key Market Trends & Insights

• Small Molecule platforms dominated the market in 2025 with USD 2.45 Billion, accounting for nearly 74% of total revenue.
• Large Molecule platforms are expected to grow faster than Small Molecules, recording a 15.6% CAGR through 2033.
• Biopharmaceutical Companies were the largest end-use segment in 2025, generating USD 1.78 Billion, and are forecast to reach USD 5.11 Billion by 2033.
• Academic & Research Institutes are projected to be the fastest-growing end-user category, expanding at a 15.5% CAGR during 2026-2033.
• Lead Discovery was the leading application segment in 2025 with USD 861.0 Million, maintaining its dominance through the forecast period.
• Target Validation is expected to be the fastest-growing major application segment, registering a 15.9% CAGR through 2033.
• Oncology represented the largest therapeutic area in 2025, accounting for USD 1.08 Billion in market revenue and is projected to exceed USD 3.01 Billion by 2033.
• Digestive System Diseases is forecast to be the fastest-growing major therapeutic segment, expanding at a 16.0% CAGR during the forecast period.
• North America was the largest regional market in 2025 with USD 1.38 Billion, while Asia Pacific is expected to record the fastest growth among major regions at a 15.8% CAGR through 2033.

The market is witnessing robust growth due to increasing pharmaceutical R&D expenditure, rising adoption of AI-enabled drug discovery technologies, growing demand for precision medicine, expansion of biologics pipelines, and the need to improve R&D productivity. Organizations are increasingly investing in cloud-based collaborative platforms, predictive analytics, and automated discovery workflows to shorten development cycles and reduce costs. Furthermore, growing interest in drug repurposing, rare disease therapeutics, and personalized medicine continues to create significant opportunities for advanced drug discovery platforms globally.

The Drug Discovery Platforms Market is characterized by a moderately fragmented yet innovation-intensive competitive environment consisting of AI-driven drug discovery companies, computational chemistry providers, biosimulation vendors, bioinformatics firms, life science software companies, and scientific informatics providers. Competition is primarily centered on predictive accuracy, AI capabilities, platform scalability, cloud integration, workflow automation, and multi-omics analytics. Companies increasingly invest in generative AI, molecular simulations, knowledge graphs, high-throughput screening technologies, and integrated research ecosystems to strengthen their market positions. Strategic collaborations among pharmaceutical companies, technology vendors, academic institutions, and research organizations continue to shape competitive dynamics across the industry.

Drivers

• Accelerated R&D Through AI-Driven and Cloud-Based Drug Discovery Platforms
• Emergence of Precision Medicine and Targeted Therapeutics
• Increasing Adoption of AI and Machine Learning for Rare Disease Drug Development
• Growing Need to Address Drug Development Challenges Through Integrated Discovery Solutions

Restraints

• High Costs and Financial Barriers in Technology Adoption
• Complex Regulatory Compliance and Validation Requirements
• Data Management Challenges and Integration Limitations

Opportunities

• Accelerated Integration of Artificial Intelligence for Predictive Drug Discovery
• Expansion of Drug Repurposing Solutions Leveraging In-Silico Clinical Models
• Adoption of Cell-Free Protein Synthesis Technologies for Novel Target Discovery

Challenges

• Technological Integration and Data Interoperability Limitations
• Regulatory and Compliance Constraints on AI-Driven Drug Discovery
• High Operational Costs and Accessibility Barriers

Market Share Analysis

The Drug Discovery Platforms Market exhibits a moderately consolidated structure where the top ten companies collectively account for approximately 77.62% of global market revenue. Schrodinger leads the market with a 13.24% share, followed by Certara and Dassault Systemes. Other major participants include Thermo Fisher Scientific, Merck KGaA, Insilico Medicine, Genedata, Optibrium, HitGen, and Relay Therapeutics. Competition increasingly revolves around AI-driven discovery capabilities, computational chemistry, biosimulation, bioinformatics, cloud-based scientific research platforms, and integrated pharmaceutical R&D ecosystems. The convergence of artificial intelligence, computational biology, molecular simulations, and multi-omics analytics continues to reshape competitive dynamics globally.

Drug Type Outlook

Based on Drug Type, the market is segmented into Small Molecule and Large Molecule. The Small Molecule market dominated the Global Drug Discovery Platforms Market by Drug Type in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 7137.8 Million by 2033, growing at a CAGR of 14.6 % during the forecast period. The Large Molecule market is expected to witness a CAGR of 15.6% during (2026 - 2033).

Small Molecule platforms account for the dominant share due to extensive utilization in traditional pharmaceutical development, high-throughput screening, computational chemistry, and structure-based drug design applications. Large Molecule platforms are experiencing strong growth driven by increasing development of biologics, monoclonal antibodies, peptides, recombinant proteins, cell therapies, and gene therapies. The growing adoption of protein engineering, bioinformatics, and advanced biologics discovery technologies continues to strengthen demand for large molecule discovery platforms.

Application Outlook

Based on Application, the market is segmented into Lead Discovery, Lead Optimization, Target Identification, Preclinical Testing, Target Validation, and Other Applications. The Lead Discovery market dominated the Global Drug Discovery Platforms Market by Application in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 2371.4 Million by 2033, growing at a CAGR of 13.7 % during the forecast period. The Lead Optimization market is expected to witness a CAGR of 14.6% during (2026 - 2033).

Lead Discovery represents a major segment due to extensive deployment of virtual screening, high-throughput screening, and AI-enabled compound identification technologies. Lead Optimization continues to gain importance through predictive modeling and medicinal chemistry applications. Target Identification and Target Validation are witnessing increased adoption driven by genomics, proteomics, CRISPR-based research, and precision medicine initiatives. Preclinical Testing platforms continue to benefit from increasing use of AI-assisted toxicology prediction and organ-on-chip technologies.

End User Outlook

Based on End Use, the market is segmented into Biopharmaceutical Companies, CROs/CDMOs, and Academic & Research Institutes. The Biopharmaceutical Companies market dominated the Global Drug Discovery Platforms Market by End Use in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 5111.9 Million by 2033, growing at a CAGR of 14.3 % during the forecast period. The CROs/CDMO market is expected to witness a CAGR of 15.4% during (2026 - 2033). The Academic and Research Institutes market is expected to witness a CAGR of 15.5% during (2026 - 2033).

Biopharmaceutical Companies account for the largest market share due to extensive investment in R&D, drug pipeline expansion, and AI-enabled drug development initiatives. CROs/CDMOs represent a rapidly growing segment as pharmaceutical companies increasingly outsource discovery and development activities. Academic and Research Institutes continue to play a vital role in target discovery, biomarker identification, and translational research initiatives that support future pharmaceutical innovation.

Therapeutic Area Outlook

Based on Therapeutic Area, the market is segmented into Oncology, Infectious & Immune System Diseases, Neurology, Cardiovascular Diseases, Digestive System Diseases, and Other Therapeutic Areas. Oncology remains the largest segment owing to extensive cancer research, immuno-oncology advancements, precision medicine initiatives, and increasing demand for targeted therapies. Infectious & Immune System Diseases continue to benefit from growing antimicrobial resistance concerns and emerging infectious disease threats. Neurology is witnessing strong growth driven by increasing investment in neurodegenerative disease therapies, while cardiovascular and digestive system disease research continues to generate substantial platform demand.

Regional Outlook

Region-wise, the Drug Discovery Platforms Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America market dominated the Global Drug Discovery Platforms Market by Region in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 3930.4 Million by 2033, growing at a CAGR of 14.2 % during the forecast period. The Europe market is expected to witness a CAGR of 14.4% during (2026 - 2033). Additionally, The Asia Pacific market is expected to witness a CAGR of 15.8% during (2026 - 2033).

North America dominates the market due to strong pharmaceutical R&D investments, widespread AI adoption, advanced biotechnology infrastructure, and the presence of leading platform providers. Europe remains a major market supported by strong academic research ecosystems, precision medicine initiatives, and regulatory support for digital health innovation. Asia Pacific is expected to witness the fastest growth due to increasing pharmaceutical manufacturing activities, expanding biotech ecosystems, rising healthcare investments, and government support for life sciences innovation. LAMEA is gradually emerging as a growth region driven by expanding healthcare infrastructure and pharmaceutical research initiatives.

Recent Strategies Deployed in the Market

• Schrodinger expanded its computational drug discovery platform capabilities to strengthen molecular simulation, predictive chemistry, and AI-assisted therapeutic development workflows.
• Insilico Medicine accelerated AI-driven precision medicine and generative AI-powered drug discovery initiatives.
• Thermo Fisher Scientific expanded integrated drug discovery and development platform services supporting biologics and laboratory automation workflows.
• Genedata expanded scientific informatics and automated data analytics solutions for biopharmaceutical research.
• Merck KGaA partnered with Mayo Clinic to strengthen AI-enabled drug development and predictive analytics capabilities.
• Certara expanded its D360 scientific informatics ecosystem to improve interoperability and collaborative pharmaceutical research.
• Insilico Medicine expanded its international presence following its Hong Kong listing, strengthening global adoption of AI-powered drug discovery technologies.
• Industry participants continue investing heavily in generative AI, computational biology, biosimulation, and cloud-native discovery ecosystems.

List of Key Companies Profiled

• Schrodinger, Inc.
• Certara, Inc.
• Dassault Systemes SE
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Insilico Medicine
• Genedata AG
• Optibrium Ltd.
• HitGen Inc.
• Relay Therapeutics, Inc.

Global Drug Discovery Platforms Market Report Segmentation

By Drug Type

• Small Molecule
• Large Molecule

By Application

• Lead Discovery
• Lead Optimization
• Target Identification
• Preclinical Testing
• Target Validation
• Other Applications

By End Use

• Biopharmaceutical Companies
• CROs/CDMOs
• Academic & Research Institutes

By Therapeutic Area

• Oncology
• Infectious & Immune System Diseases
• Neurology
• Cardiovascular Diseases
• Digestive System Diseases
• Other Therapeutic Areas

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Research Scope & Methodology

• 1.1 Market Definition
• 1.2 Analysis Period & Currency
• 1.3 Segmentation
• 1.4 Drug Discovery Platforms Market, by Geography
• 1.5 Research Methodology

Chapter 2. Market Overview

• 2.1 COVID-19 Impact
• 2.2 Market Composition and Scenario

Chapter 3. Key Factors Impacting Market

• 3.1 Market Drivers
• 3.2 Market Restraints
• 3.3 Market Opportunities
• 3.4 Market Challenges
• 3.5 Market Trends
• 3.6 State of Competition
• 3.7 Market Consolidation
• 3.8 Key Customer Criteria

Chapter 4. Product Life Cycle

Chapter 5. Value Chain Analysis

Chapter 6. Competition Analysis - Global

• 6.1 Market Share Analysis
• 6.2 Recent Developments and Strategies
  • 6.2.1 Product Launch & Product Expansion
  • 6.2.2 Partnership, Collaboration & Agreements
  • 6.2.3 Geographical Expansion

Chapter 7. Segmentation By Drug Type

• 7.1 Small Molecule
• 7.2 Large Molecule

Chapter 8. Segmentation By End Use

• 8.1 Biopharmaceutical Companies
• 8.2 CROs/CDMOs
• 8.3 Academic and Research Institutes

Chapter 9. Segmentation By Application

• 9.1 Lead Discovery
• 9.2 Lead Optimization
• 9.3 Target Identification
• 9.4 Preclinical Testing
• 9.5 Target Validation
• 9.6 Other Application

Chapter 10. Segmentation By Therapeutic

• 10.1 Oncology
• 10.2 Infectious and Immune System Diseases
• 10.3 Neurology
• 10.4 Cardiovascular Diseases
• 10.5 Digestive System Diseases
• 10.6 Other Therapeutic

Chapter 11. North America Market

• 11.1 Market Overview
• 11.2 Key Factors Impacting Market
  • 11.2.1 Market Drivers
  • 11.2.2 Market Restraints
  • 11.2.3 Market Opportunities
  • 11.2.4 Market Challenges
  • 11.2.5 Market Trends
  • 11.2.6 State of Competition
  • 11.2.7 Market Consolidation
  • 11.2.8 Key Customer Criteria
• 11.3 Product Life Cycle
• 11.4 Segmentation By Drug Type
  • 11.4.1 Small Molecule
  • 11.4.2 Large Molecule
• 11.5 Segmentation By End Use
  • 11.5.1 Biopharmaceutical Companies
  • 11.5.2 CROs/CDMOs
  • 11.5.3 Academic and Research Institutes
• 11.6 Segmentation By Application
  • 11.6.1 Lead Discovery
  • 11.6.2 Lead Optimization
  • 11.6.3 Target Identification
  • 11.6.4 Preclinical Testing
  • 11.6.5 Target Validation
  • 11.6.6 Other Application
• 11.7 Segmentation By Therapeutic
  • 11.7.1 Oncology
  • 11.7.2 Infectious and Immune System Diseases
  • 11.7.3 Neurology
  • 11.7.4 Cardiovascular Diseases
  • 11.7.5 Digestive System Diseases
  • 11.7.6 Other Therapeutic
• 11.8 Segmentation By Country
  • 11.8.1 US
    • 11.8.1.1 Segmentation By Drug Type
      • 11.8.1.1.1 Small Molecule
      • 11.8.1.1.2 Large Molecule
    • 11.8.1.2 Segmentation By End Use
      • 11.8.1.2.1 Biopharmaceutical Companies
      • 11.8.1.2.2 CROs/CDMOs
      • 11.8.1.2.3 Academic and Research Institutes
    • 11.8.1.3 Segmentation By Application
      • 11.8.1.3.1 Lead Discovery
      • 11.8.1.3.2 Lead Optimization
      • 11.8.1.3.3 Target Identification
      • 11.8.1.3.4 Preclinical Testing
      • 11.8.1.3.5 Target Validation
      • 11.8.1.3.6 Other Application
    • 11.8.1.4 Segmentation By Therapeutic
      • 11.8.1.4.1 Oncology
      • 11.8.1.4.2 Infectious and Immune System Diseases
      • 11.8.1.4.3 Neurology
      • 11.8.1.4.4 Cardiovascular Diseases
      • 11.8.1.4.5 Digestive System Diseases
      • 11.8.1.4.6 Other Therapeutic
  • 11.8.2 Canada
    • 11.8.2.1 Segmentation By Drug Type
      • 11.8.2.1.1 Small Molecule
      • 11.8.2.1.2 Large Molecule
    • 11.8.2.2 Segmentation By End Use
      • 11.8.2.2.1 Biopharmaceutical Companies
      • 11.8.2.2.2 CROs/CDMOs
      • 11.8.2.2.3 Academic and Research Institutes
    • 11.8.2.3 Segmentation By Application
      • 11.8.2.3.1 Lead Discovery
      • 11.8.2.3.2 Lead Optimization
      • 11.8.2.3.3 Target Identification
      • 11.8.2.3.4 Preclinical Testing
      • 11.8.2.3.5 Target Validation
      • 11.8.2.3.6 Other Application
    • 11.8.2.4 Segmentation By Therapeutic
      • 11.8.2.4.1 Oncology
      • 11.8.2.4.2 Infectious and Immune System Diseases
      • 11.8.2.4.3 Neurology
      • 11.8.2.4.4 Cardiovascular Diseases
      • 11.8.2.4.5 Digestive System Diseases
      • 11.8.2.4.6 Other Therapeutic
  • 11.8.3 Mexico
    • 11.8.3.1 Segmentation By Drug Type
      • 11.8.3.1.1 Small Molecule
      • 11.8.3.1.2 Large Molecule
    • 11.8.3.2 Segmentation By End Use
      • 11.8.3.2.1 Biopharmaceutical Companies
      • 11.8.3.2.2 CROs/CDMOs
      • 11.8.3.2.3 Academic and Research Institutes
    • 11.8.3.3 Segmentation By Application
      • 11.8.3.3.1 Lead Discovery
      • 11.8.3.3.2 Lead Optimization
      • 11.8.3.3.3 Target Identification
      • 11.8.3.3.4 Preclinical Testing
      • 11.8.3.3.5 Target Validation
      • 11.8.3.3.6 Other Application
    • 11.8.3.4 Segmentation By Therapeutic
      • 11.8.3.4.1 Oncology
      • 11.8.3.4.2 Infectious and Immune System Diseases
      • 11.8.3.4.3 Neurology
      • 11.8.3.4.4 Cardiovascular Diseases
      • 11.8.3.4.5 Digestive System Diseases
      • 11.8.3.4.6 Other Therapeutic
  • 11.8.4 Rest of North America
    • 11.8.4.1 Segmentation By Drug Type
      • 11.8.4.1.1 Small Molecule
      • 11.8.4.1.2 Large Molecule
    • 11.8.4.2 Segmentation By End Use
      • 11.8.4.2.1 Biopharmaceutical Companies
      • 11.8.4.2.2 CROs/CDMOs
      • 11.8.4.2.3 Academic and Research Institutes
    • 11.8.4.3 Segmentation By Application
      • 11.8.4.3.1 Lead Discovery
      • 11.8.4.3.2 Lead Optimization
      • 11.8.4.3.3 Target Identification
      • 11.8.4.3.4 Preclinical Testing
      • 11.8.4.3.5 Target Validation
      • 11.8.4.3.6 Other Application
    • 11.8.4.4 Segmentation By Therapeutic
      • 11.8.4.4.1 Oncology
      • 11.8.4.4.2 Infectious and Immune System Diseases
      • 11.8.4.4.3 Neurology
      • 11.8.4.4.4 Cardiovascular Diseases
      • 11.8.4.4.5 Digestive System Diseases
      • 11.8.4.4.6 Other Therapeutic

Chapter 12. Europe Market

• 12.1 Market Overview
• 12.2 Key Factors Impacting Market
  • 12.2.1 Market Drivers
  • 12.2.2 Market Restraints
  • 12.2.3 Market Opportunities
  • 12.2.4 Market Challenges
  • 12.2.5 Market Trends
  • 12.2.6 State of Competition
  • 12.2.7 Market Consolidation
  • 12.2.8 Key Customer Criteria
• 12.3 Product Life Cycle
• 12.4 Segmentation By Drug Type
  • 12.4.1 Small Molecule
  • 12.4.2 Large Molecule
• 12.5 Segmentation By End Use
  • 12.5.1 Biopharmaceutical Companies
  • 12.5.2 CROs/CDMO
  • 12.5.3 Academic and Research Institutes
• 12.6 Segmentation By Application
  • 12.6.1 Lead Discovery
  • 12.6.2 Lead Optimization
  • 12.6.3 Target Identification
  • 12.6.4 Preclinical Testing
  • 12.6.5 Target Validation
  • 12.6.6 Other Applications
• 12.7 Segmentation By Therapeutic
  • 12.7.1 Oncology
  • 12.7.2 Infectious and Immune System Diseases
  • 12.7.3 Neurology
  • 12.7.4 Cardiovascular Diseases
  • 12.7.5 Digestive System Diseases
  • 12.7.6 Other Therapeutic
• 12.8 Segmentation By Country
  • 12.8.1 Germany
    • 12.8.1.1 Segmentation By Drug Type
      • 12.8.1.1.1 Small Molecule
      • 12.8.1.1.2 Large Molecule
    • 12.8.1.2 Segmentation By End Use
      • 12.8.1.2.1 Biopharmaceutical Companies
      • 12.8.1.2.2 CROs/CDMOs
      • 12.8.1.2.3 Academic and Research Institutes
    • 12.8.1.3 Segmentation By Application
      • 12.8.1.3.1 Lead Discovery
      • 12.8.1.3.2 Lead Optimization
      • 12.8.1.3.3 Target Identification
      • 12.8.1.3.4 Preclinical Testing
      • 12.8.1.3.5 Target Validation
      • 12.8.1.3.6 Other Application
    • 12.8.1.4 Segmentation By Therapeutic
      • 12.8.1.4.1 Oncology
      • 12.8.1.4.2 Infectious and Immune System Diseases
      • 12.8.1.4.3 Neurology
      • 12.8.1.4.4 Cardiovascular Diseases
      • 12.8.1.4.5 Digestive System Diseases
      • 12.8.1.4.6 Other Therapeutic
  • 12.8.2 UK
    • 12.8.2.1 Segmentation By Drug Type
      • 12.8.2.1.1 Small Molecule
      • 12.8.2.1.2 Large Molecule
    • 12.8.2.2 Segmentation By End Use
      • 12.8.2.2.1 Biopharmaceutical Companies
      • 12.8.2.2.2 CROs/CDMOs
      • 12.8.2.2.3 Academic and Research Institutes
    • 12.8.2.3 Segmentation By Application
      • 12.8.2.3.1 Lead Discovery
      • 12.8.2.3.2 Lead Optimization
      • 12.8.2.3.3 Target Identification
      • 12.8.2.3.4 Preclinical Testing
      • 12.8.2.3.5 Target Validation
      • 12.8.2.3.6 Other Application
    • 12.8.2.4 Segmentation By Therapeutic
      • 12.8.2.4.1 Oncology
      • 12.8.2.4.2 Infectious and Immune System Diseases
      • 12.8.2.4.3 Neurology
      • 12.8.2.4.4 Cardiovascular Diseases
      • 12.8.2.4.5 Digestive System Diseases
      • 12.8.2.4.6 Other Therapeutic
  • 12.8.3 France
    • 12.8.3.1 Segmentation By Drug Type
      • 12.8.3.1.1 Small Molecule
      • 12.8.3.1.2 Large Molecule
    • 12.8.3.2 Segmentation By End Use
      • 12.8.3.2.1 Biopharmaceutical Companies
      • 12.8.3.2.2 CROs/CDMOs
      • 12.8.3.2.3 Academic and Research Institutes
    • 12.8.3.3 Segmentation By Application
      • 12.8.3.3.1 Lead Discovery
      • 12.8.3.3.2 Lead Optimization
      • 12.8.3.3.3 Target Identification
      • 12.8.3.3.4 Preclinical Testing
      • 12.8.3.3.5 Target Validation
      • 12.8.3.3.6 Other Application
    • 12.8.3.4 Segmentation By Therapeutic
      • 12.8.3.4.1 Oncology
      • 12.8.3.4.2 Infectious and Immune System Diseases
      • 12.8.3.4.3 Neurology
      • 12.8.3.4.4 Cardiovascular Diseases
      • 12.8.3.4.5 Digestive System Diseases
      • 12.8.3.4.6 Other Therapeutic
  • 12.8.4 Russia
    • 12.8.4.1 Segmentation By Drug Type
      • 12.8.4.1.1 Small Molecule
      • 12.8.4.1.2 Large Molecule
    • 12.8.4.2 Segmentation By End Use
      • 12.8.4.2.1 Biopharmaceutical Companies
      • 12.8.4.2.2 CROs/CDMOs
      • 12.8.4.2.3 Academic and Research Institutes
    • 12.8.4.3 Segmentation By Application
      • 12.8.4.3.1 Lead Discovery
      • 12.8.4.3.2 Lead Optimization
      • 12.8.4.3.3 Target Identification
      • 12.8.4.3.4 Preclinical Testing
      • 12.8.4.3.5 Target Validation
      • 12.8.4.3.6 Other Application
    • 12.8.4.4 Segmentation By Therapeutic
      • 12.8.4.4.1 Oncology
      • 12.8.4.4.2 Infectious and Immune System Diseases
      • 12.8.4.4.3 Neurology
      • 12.8.4.4.4 Cardiovascular Diseases
      • 12.8.4.4.5 Digestive System Diseases
      • 12.8.4.4.6 Other Therapeutic
  • 12.8.5 Spain
    • 12.8.5.1 Segmentation By Drug Type
      • 12.8.5.1.1 Small Molecule
      • 12.8.5.1.2 Large Molecule
    • 12.8.5.2 Segmentation By End Use
      • 12.8.5.2.1 Biopharmaceutical Companies
      • 12.8.5.2.2 CROs/CDMOs
      • 12.8.5.2.3 Academic and Research Institutes
    • 12.8.5.3 Segmentation By Application
      • 12.8.5.3.1 Lead Discovery
      • 12.8.5.3.2 Lead Optimization
      • 12.8.5.3.3 Target Identification
      • 12.8.5.3.4 Preclinical Testing
      • 12.8.5.3.5 Target Validation
      • 12.8.5.3.6 Other Application
    • 12.8.5.4 Segmentation By Therapeutic
      • 12.8.5.4.1 Oncology
      • 12.8.5.4.2 Infectious and Immune System Diseases
      • 12.8.5.4.3 Neurology
      • 12.8.5.4.4 Cardiovascular Diseases
      • 12.8.5.4.5 Digestive System Diseases
      • 12.8.5.4.6 Other Therapeutic
  • 12.8.6 Italy
    • 12.8.6.1 Segmentation By Drug Type
      • 12.8.6.1.1 Small Molecule
      • 12.8.6.1.2 Large Molecule
    • 12.8.6.2 Segmentation By End Use
      • 12.8.6.2.1 Biopharmaceutical Companies
      • 12.8.6.2.2 CROs/CDMOs
      • 12.8.6.2.3 Academic and Research Institutes
    • 12.8.6.3 Segmentation By Application
      • 12.8.6.3.1 Lead Discovery
      • 12.8.6.3.2 Lead Optimization
      • 12.8.6.3.3 Target Identification
      • 12.8.6.3.4 Preclinical Testing
      • 12.8.6.3.5 Target Validation
      • 12.8.6.3.6 Other Application
    • 12.8.6.4 Segmentation By Therapeutic
      • 12.8.6.4.1 Oncology
      • 12.8.6.4.2 Infectious and Immune System Diseases
      • 12.8.6.4.3 Neurology
      • 12.8.6.4.4 Cardiovascular Diseases
      • 12.8.6.4.5 Digestive System Diseases
      • 12.8.6.4.6 Other Therapeutic
  • 12.8.7 Rest of Europe
    • 12.8.7.1 Segmentation By Drug Type
      • 12.8.7.1.1 Small Molecule
      • 12.8.7.1.2 Large Molecule
    • 12.8.7.2 Segmentation By End Use
      • 12.8.7.2.1 Biopharmaceutical Companies
      • 12.8.7.2.2 CROs/CDMOs
      • 12.8.7.2.3 Academic and Research Institutes
    • 12.8.7.3 Segmentation By Application
      • 12.8.7.3.1 Lead Discovery
      • 12.8.7.3.2 Lead Optimization
      • 12.8.7.3.3 Target Identification
      • 12.8.7.3.4 Preclinical Testing
      • 12.8.7.3.5 Target Validation
      • 12.8.7.3.6 Other Application
    • 12.8.7.4 Segmentation By Therapeutic
      • 12.8.7.4.1 Oncology
      • 12.8.7.4.2 Infectious and Immune System Diseases
      • 12.8.7.4.3 Neurology
      • 12.8.7.4.4 Cardiovascular Diseases
      • 12.8.7.4.5 Digestive System Diseases
      • 12.8.7.4.6 Other Therapeutic

Chapter 13. Asia Pacific Market

• 13.1 Market Overview
• 13.2 Key Factors Impacting Market
  • 13.2.1 Market Drivers
  • 13.2.2 Market Restraints
  • 13.2.3 Market Opportunities
  • 13.2.4 Market Challenges
  • 13.2.5 Market Trends
  • 13.2.6 Market Consolidation
  • 13.2.7 Key Customer Criteria
• 13.3 Product Life Cycle
• 13.4 Segmentation By Drug Type
  • 13.4.1 Small Molecule
  • 13.4.2 Large Molecule
• 13.5 Segmentation By End Use
  • 13.5.1 Biopharmaceutical Companies
  • 13.5.2 CROs/CDMOs
  • 13.5.3 Academic and Research Institutes
• 13.6 Segmentation By Application
  • 13.6.1 Lead Discovery
  • 13.6.2 Lead Optimization
  • 13.6.3 Target Identification
  • 13.6.4 Target Validation
  • 13.6.5 Preclinical Testing
  • 13.6.6 Other Application
• 13.7 Segmentation By Therapeutic
  • 13.7.1 Oncology
  • 13.7.2 Neurology
  • 13.7.3 Cardiovascular Diseases
  • 13.7.4 Digestive System Diseases
  • 13.7.5 Other Therapeutic
• 13.8 Segmentation By Country
  • 13.8.1 China
    • 13.8.1.1 Segmentation By Drug Type
      • 13.8.1.1.1 Small Molecule
      • 13.8.1.1.2 Large Molecule
    • 13.8.1.2 Segmentation By End Use
      • 13.8.1.2.1 Biopharmaceutical Companies
      • 13.8.1.2.2 CROs/CDMOs
      • 13.8.1.2.3 Academic and Research Institutes
    • 13.8.1.3 Segmentation By Application
      • 13.8.1.3.1 Lead Discovery
      • 13.8.1.3.2 Lead Optimization
      • 13.8.1.3.3 Target Identification
      • 13.8.1.3.4 Preclinical Testing
      • 13.8.1.3.5 Target Validation
      • 13.8.1.3.6 Other Application
    • 13.8.1.4 Segmentation By Therapeutic
      • 13.8.1.4.1 Oncology
      • 13.8.1.4.2 Infectious and Immune System Diseases
      • 13.8.1.4.3 Neurology
      • 13.8.1.4.4 Cardiovascular Diseases
      • 13.8.1.4.5 Digestive System Diseases
      • 13.8.1.4.6 Other Therapeutic
  • 13.8.2 Japan
    • 13.8.2.1 Segmentation By Drug Type
      • 13.8.2.1.1 Small Molecule
      • 13.8.2.1.2 Large Molecule
    • 13.8.2.2 Segmentation By End Use
      • 13.8.2.2.1 Biopharmaceutical Companies
      • 13.8.2.2.2 CROs/CDMOs
      • 13.8.2.2.3 Academic and Research Institutes
    • 13.8.2.3 Segmentation By Application
      • 13.8.2.3.1 Lead Discovery
      • 13.8.2.3.2 Lead Optimization
      • 13.8.2.3.3 Target Identification
      • 13.8.2.3.4 Preclinical Testing
      • 13.8.2.3.5 Target Validation
      • 13.8.2.3.6 Other Application
    • 13.8.2.4 Segmentation By Therapeutic
      • 13.8.2.4.1 Oncology
      • 13.8.2.4.2 Infectious and Immune System Diseases
      • 13.8.2.4.3 Neurology
      • 13.8.2.4.4 Cardiovascular Diseases
      • 13.8.2.4.5 Digestive System Diseases
      • 13.8.2.4.6 Other Therapeutic
  • 13.8.3 India
    • 13.8.3.1 Segmentation By Drug Type
      • 13.8.3.1.1 Small Molecule
      • 13.8.3.1.2 Large Molecule
    • 13.8.3.2 Segmentation By End Use
      • 13.8.3.2.1 Biopharmaceutical Companies
      • 13.8.3.2.2 CROs/CDMOs
      • 13.8.3.2.3 Academic and Research Institutes
    • 13.8.3.3 Segmentation By Application
      • 13.8.3.3.1 Lead Discovery
      • 13.8.3.3.2 Lead Optimization
      • 13.8.3.3.3 Target Identification
      • 13.8.3.3.4 Preclinical Testing
      • 13.8.3.3.5 Target Validation
      • 13.8.3.3.6 Other Application
    • 13.8.3.4 Segmentation By Therapeutic
      • 13.8.3.4.1 Oncology
      • 13.8.3.4.2 Infectious and Immune System Diseases
      • 13.8.3.4.3 Neurology
      • 13.8.3.4.4 Cardiovascular Diseases
      • 13.8.3.4.5 Digestive System Diseases
      • 13.8.3.4.6 Other Therapeutic
  • 13.8.4 South Korea
    • 13.8.4.1 Segmentation By Drug Type
      • 13.8.4.1.1 Small Molecule
      • 13.8.4.1.2 Large Molecule
    • 13.8.4.2 Segmentation By End Use
      • 13.8.4.2.1 Biopharmaceutical Companies
      • 13.8.4.2.2 CROs/CDMOs
      • 13.8.4.2.3 Academic and Research Institutes
    • 13.8.4.3 Segmentation By Application
      • 13.8.4.3.1 Lead Discovery
      • 13.8.4.3.2 Lead Optimization
      • 13.8.4.3.3 Target Identification
      • 13.8.4.3.4 Preclinical Testing
      • 13.8.4.3.5 Target Validation
      • 13.8.4.3.6 Other Application
    • 13.8.4.4 Segmentation By Therapeutic
      • 13.8.4.4.1 Oncology
      • 13.8.4.4.2 Infectious and Immune System Diseases
      • 13.8.4.4.3 Neurology
      • 13.8.4.4.4 Cardiovascular Diseases
      • 13.8.4.4.5 Digestive System Diseases
      • 13.8.4.4.6 Other Therapeutic
  • 13.8.5 Singapore
    • 13.8.5.1 Segmentation By Drug Type
      • 13.8.5.1.1 Small Molecule
      • 13.8.5.1.2 Large Molecule
    • 13.8.5.2 Segmentation By End Use
      • 13.8.5.2.1 Biopharmaceutical Companies
      • 13.8.5.2.2 CROs/CDMOs
      • 13.8.5.2.3 Academic and Research Institutes
    • 13.8.5.3 Segmentation By Application
      • 13.8.5.3.1 Lead Discovery
      • 13.8.5.3.2 Lead Optimization
      • 13.8.5.3.3 Target Identification
      • 13.8.5.3.4 Preclinical Testing
      • 13.8.5.3.5 Target Validation
      • 13.8.5.3.6 Other Application
    • 13.8.5.4 Segmentation By Therapeutic
      • 13.8.5.4.1 Oncology
      • 13.8.5.4.2 Infectious and Immune System Diseases
      • 13.8.5.4.3 Neurology
      • 13.8.5.4.4 Cardiovascular Diseases
      • 13.8.5.4.5 Digestive System Diseases
      • 13.8.5.4.6 Other Therapeutic
  • 13.8.6 Malaysia
    • 13.8.6.1 Segmentation By Drug Type
      • 13.8.6.1.1 Small Molecule
      • 13.8.6.1.2 Large Molecule
    • 13.8.6.2 Segmentation By End Use
      • 13.8.6.2.1 Biopharmaceutical Companies
      • 13.8.6.2.2 CROs/CDMOs
      • 13.8.6.2.3 Academic and Research Institutes
    • 13.8.6.3 Segmentation By Application
      • 13.8.6.3.1 Lead Discovery
      • 13.8.6.3.2 Lead Optimization
      • 13.8.6.3.3 Target Identification
      • 13.8.6.3.4 Preclinical Testing
      • 13.8.6.3.5 Target Validation
      • 13.8.6.3.6 Other Application
    • 13.8.6.4 Segmentation By Therapeutic
      • 13.8.6.4.1 Oncology
      • 13.8.6.4.2 Infectious and Immune System Diseases
      • 13.8.6.4.3 Neurology
      • 13.8.6.4.4 Cardiovascular Diseases
      • 13.8.6.4.5 Digestive System Diseases
      • 13.8.6.4.6 Other Therapeutic
  • 13.8.7 Rest of Asia Pacific
    • 13.8.7.1 Segmentation By Drug Type
      • 13.8.7.1.1 Small Molecule
      • 13.8.7.1.2 Large Molecule
    • 13.8.7.2 Segmentation By End Use
      • 13.8.7.2.1 Biopharmaceutical Companies
      • 13.8.7.2.2 CROs/CDMOs
      • 13.8.7.2.3 Academic and Research Institutes
    • 13.8.7.3 Segmentation By Application
      • 13.8.7.3.1 Lead Discovery
      • 13.8.7.3.2 Lead Optimization
      • 13.8.7.3.3 Target Identification
      • 13.8.7.3.4 Preclinical Testing
      • 13.8.7.3.5 Target Validation
      • 13.8.7.3.6 Other Application
    • 13.8.7.4 Segmentation By Therapeutic
      • 13.8.7.4.1 Oncology
      • 13.8.7.4.2 Infectious and Immune System Diseases
      • 13.8.7.4.3 Neurology
      • 13.8.7.4.4 Cardiovascular Diseases
      • 13.8.7.4.5 Digestive System Diseases
      • 13.8.7.4.6 Other Therapeutic

Chapter 14. LAMEA Market

• 14.1 Market Overview
• 14.2 Key Factors Impacting Market
  • 14.2.1 Market Drivers
  • 14.2.2 Market Restraints
  • 14.2.3 Market Opportunities
  • 14.2.4 Market Challenges
  • 14.2.5 Market Trends
  • 14.2.6 State of Competition
  • 14.2.7 Market Consolidation
  • 14.2.8 Key Customer Criteria
• 14.3 Product Life Cycle
• 14.4 Segmentation By Drug Type
  • 14.4.1 Small Molecule
  • 14.4.2 Large Molecule
• 14.5 Segmentation By End Use
  • 14.5.1 Pharmaceutical Companies
  • 14.5.2 CROs/CDMOs
  • 14.5.3 Academic and Research Institutes
• 14.6 By Application Segmentation
  • 14.6.1 Lead Discovery
  • 14.6.2 Lead Optimization
  • 14.6.3 Target Identification
  • 14.6.4 Preclinical Testing
  • 14.6.5 Target Validation
  • 14.6.6 Other Application
• 14.7 Segmentation By Therapeutic
  • 14.7.1 Oncology
  • 14.7.2 Infectious and Immune System Diseases
  • 14.7.3 Neurology
  • 14.7.4 Cardiovascular Diseases
  • 14.7.5 Digestive System Diseases
  • 14.7.6 Other Therapeutic
• 14.8 Segmentation By Country
  • 14.8.1 Brazil
    • 14.8.1.1 Segmentation By Drug Type
      • 14.8.1.1.1 Small Molecule
      • 14.8.1.1.2 Large Molecule
    • 14.8.1.2 Segmentation By End Use
      • 14.8.1.2.1 Biopharmaceutical Companies
      • 14.8.1.2.2 CROs/CDMOs
      • 14.8.1.2.3 Academic and Research Institutes
    • 14.8.1.3 Segmentation By Application
      • 14.8.1.3.1 Lead Discovery
      • 14.8.1.3.2 Lead Optimization
      • 14.8.1.3.3 Target Identification
      • 14.8.1.3.4 Preclinical Testing
      • 14.8.1.3.5 Target Validation
      • 14.8.1.3.6 Other Application
    • 14.8.1.4 Segmentation By Therapeutic
      • 14.8.1.4.1 Oncology
      • 14.8.1.4.2 Infectious and Immune System Diseases
      • 14.8.1.4.3 Neurology
      • 14.8.1.4.4 Cardiovascular Diseases
      • 14.8.1.4.5 Digestive System Diseases
      • 14.8.1.4.6 Other Therapeutic
  • 14.8.2 Argentina
    • 14.8.2.1 Segmentation By Drug Type
      • 14.8.2.1.1 Small Molecule
      • 14.8.2.1.2 Large Molecule
    • 14.8.2.2 Segmentation By End Use
      • 14.8.2.2.1 Biopharmaceutical Companies
      • 14.8.2.2.2 CROs/CDMOs
      • 14.8.2.2.3 Academic and Research Institutes
    • 14.8.2.3 Segmentation By Application
      • 14.8.2.3.1 Lead Discovery
      • 14.8.2.3.2 Lead Optimization
      • 14.8.2.3.3 Target Identification
      • 14.8.2.3.4 Preclinical Testing
      • 14.8.2.3.5 Target Validation
      • 14.8.2.3.6 Other Application
    • 14.8.2.4 Segmentation By Therapeutic
      • 14.8.2.4.1 Oncology
      • 14.8.2.4.2 Infectious and Immune System Diseases
      • 14.8.2.4.3 Neurology
      • 14.8.2.4.4 Cardiovascular Diseases
      • 14.8.2.4.5 Digestive System Diseases
      • 14.8.2.4.6 Other Therapeutic
  • 14.8.3 UAE
    • 14.8.3.1 Segmentation By Drug Type
      • 14.8.3.1.1 Small Molecule
      • 14.8.3.1.2 Large Molecule
    • 14.8.3.2 Segmentation By End Use
      • 14.8.3.2.1 Biopharmaceutical Companies
      • 14.8.3.2.2 CROs/CDMOs
      • 14.8.3.2.3 Academic and Research Institutes
    • 14.8.3.3 Segmentation By Application
      • 14.8.3.3.1 Lead Discovery
      • 14.8.3.3.2 Lead Optimization
      • 14.8.3.3.3 Target Identification
      • 14.8.3.3.4 Preclinical Testing
      • 14.8.3.3.5 Target Validation
      • 14.8.3.3.6 Other Application
    • 14.8.3.4 Segmentation By Therapeutic
      • 14.8.3.4.1 Oncology
      • 14.8.3.4.2 Infectious and Immune System Diseases
      • 14.8.3.4.3 Neurology
      • 14.8.3.4.4 Cardiovascular Diseases
      • 14.8.3.4.5 Digestive System Diseases
      • 14.8.3.4.6 Other Therapeutic
  • 14.8.4 Saudi Arabia
    • 14.8.4.1 Segmentation By Drug Type
      • 14.8.4.1.1 Small Molecule
      • 14.8.4.1.2 Large Molecule
    • 14.8.4.2 Segmentation By End Use
      • 14.8.4.2.1 Biopharmaceutical Companies
      • 14.8.4.2.2 CROs/CDMOs
      • 14.8.4.2.3 Academic and Research Institutes
    • 14.8.4.3 Segmentation By Application
      • 14.8.4.3.1 Lead Discovery
      • 14.8.4.3.2 Lead Optimization
      • 14.8.4.3.3 Target Identification
      • 14.8.4.3.4 Preclinical Testing
      • 14.8.4.3.5 Target Validation
      • 14.8.4.3.6 Other Application
    • 14.8.4.4 Segmentation By Therapeutic
      • 14.8.4.4.1 Oncology
      • 14.8.4.4.2 Infectious and Immune System Diseases
      • 14.8.4.4.3 Neurology
      • 14.8.4.4.4 Cardiovascular Diseases
      • 14.8.4.4.5 Digestive System Diseases
      • 14.8.4.4.6 Other Therapeutic
  • 14.8.5 South Africa
    • 14.8.5.1 Segmentation By Drug Type
      • 14.8.5.1.1 Small Molecule
      • 14.8.5.1.2 Large Molecule
    • 14.8.5.2 Segmentation By End Use
      • 14.8.5.2.1 Biopharmaceutical Companies
      • 14.8.5.2.2 CROs/CDMOs
      • 14.8.5.2.3 Academic and Research Institutes
    • 14.8.5.3 Segmentation By Application
      • 14.8.5.3.1 Lead Discovery
      • 14.8.5.3.2 Lead Optimization
      • 14.8.5.3.3 Target Identification
      • 14.8.5.3.4 Preclinical Testing
      • 14.8.5.3.5 Target Validation
      • 14.8.5.3.6 Other Application
    • 14.8.5.4 Segmentation By Therapeutic
      • 14.8.5.4.1 Oncology
      • 14.8.5.4.2 Infectious and Immune System Diseases
      • 14.8.5.4.3 Neurology
      • 14.8.5.4.4 Cardiovascular Diseases
      • 14.8.5.4.5 Digestive System Diseases
      • 14.8.5.4.6 Other Therapeutic
  • 14.8.6 Nigeria
    • 14.8.6.1 Segmentation By Drug Type
      • 14.8.6.1.1 Small Molecule
      • 14.8.6.1.2 Large Molecule
    • 14.8.6.2 Segmentation By End Use
      • 14.8.6.2.1 Biopharmaceutical Companies
      • 14.8.6.2.2 CROs/CDMOs
      • 14.8.6.2.3 Academic and Research Institutes
    • 14.8.6.3 Segmentation By Application
      • 14.8.6.3.1 Lead Discovery
      • 14.8.6.3.2 Lead Optimization
      • 14.8.6.3.3 Target Identification
      • 14.8.6.3.4 Preclinical Testing
      • 14.8.6.3.5 Target Validation
      • 14.8.6.3.6 Other Application
    • 14.8.6.4 Segmentation By Therapeutic
      • 14.8.6.4.1 Oncology
      • 14.8.6.4.2 Infectious and Immune System Diseases
      • 14.8.6.4.3 Neurology
      • 14.8.6.4.4 Cardiovascular Diseases
      • 14.8.6.4.5 Digestive System Diseases
      • 14.8.6.4.6 Other Therapeutic
  • 14.8.7 Rest of LAMEA
    • 14.8.7.1 Segmentation By Drug Type
      • 14.8.7.1.1 Small Molecule
      • 14.8.7.1.2 Large Molecule
    • 14.8.7.2 Segmentation By End Use
      • 14.8.7.2.1 Biopharmaceutical Companies
      • 14.8.7.2.2 CROs/CDMOs
      • 14.8.7.2.3 Academic and Research Institutes
    • 14.8.7.3 Segmentation By Application
      • 14.8.7.3.1 Lead Discovery
      • 14.8.7.3.2 Lead Optimization
      • 14.8.7.3.3 Target Identification
      • 14.8.7.3.4 Preclinical Testing
      • 14.8.7.3.5 Target Validation
      • 14.8.7.3.6 Other Application
    • 14.8.7.4 Segmentation By Therapeutic
      • 14.8.7.4.1 Oncology
      • 14.8.7.4.2 Infectious and Immune System Diseases
      • 14.8.7.4.3 Neurology
      • 14.8.7.4.4 Cardiovascular Diseases
      • 14.8.7.4.5 Digestive System Diseases
      • 14.8.7.4.6 Other Therapeutic

Chapter 15. Company Snapshot

• 15.1 Schrodinger, Inc.
  • 15.1.1 Business Overview
  • 15.1.2 Key Information
  • 15.1.3 Company Focus
  • 15.1.4 Strategic Insights
  • 15.1.5 Strategy Deployed
  • 15.1.6 Product & Service Portfolio
  • 15.1.7 Capability Overview
  • 15.1.8 Technology & Innovation Focus
  • 15.1.9 Customers / End Users
  • 15.1.10 Competitive Positioning
  • 15.1.11 Key Differentiators
  • 15.1.12 Portfolio Matrix
  • 15.1.13 SWOT Analysis
  • 15.1.14 Future Outlook
• 15.2 Certara, Inc.
  • 15.2.1 Business Overview
  • 15.2.2 Key Information
  • 15.2.3 Company Focus
  • 15.2.4 Strategic Insights
  • 15.2.5 Strategy Deployed
  • 15.2.6 Product & Service Portfolio
  • 15.2.7 Capability Overview
  • 15.2.8 Technology & Innovation Focus
  • 15.2.9 Customers / End Users
  • 15.2.10 Competitive Positioning
  • 15.2.11 Key Differentiators
  • 15.2.12 Portfolio Matrix
  • 15.2.13 SWOT Analysis
  • 15.2.14 Future Outlook
• 15.3 Optibrium Ltd.
  • 15.3.1 Business Overview
  • 15.3.2 Key Information
  • 15.3.3 Company Focus
  • 15.3.4 Strategic Insights
  • 15.3.5 Strategy Deployed
  • 15.3.6 Product & Service Portfolio
  • 15.3.7 Capability Overview
  • 15.3.8 Technology & Innovation Focus
  • 15.3.9 Customers / End Users
  • 15.3.10 Competitive Positioning
  • 15.3.11 Key Differentiators
  • 15.3.12 Portfolio Matrix
  • 15.3.13 SWOT Analysis
  • 15.3.14 Future Outlook
• 15.4 Dassault Systemes SE
  • 15.4.1 Business Overview
  • 15.4.2 Key Information
  • 15.4.3 Company Focus
  • 15.4.4 Strategic Insights
  • 15.4.5 Strategy Deployed
  • 15.4.6 Product & Service Portfolio
  • 15.4.7 Capability Overview
  • 15.4.8 Technology & Innovation Focus
  • 15.4.9 Customers / End Users
  • 15.4.10 Competitive Positioning
  • 15.4.11 Key Differentiators
  • 15.4.12 Portfolio Matrix
  • 15.4.13 SWOT Analysis
  • 15.4.14 Future Outlook
• 15.5 Insilico Medicine
  • 15.5.1 Business Overview
  • 15.5.2 Key Information
  • 15.5.3 Company Focus
  • 15.5.4 Strategic Insights
  • 15.5.5 Strategy Deployed
  • 15.5.6 Product & Service Portfolio
  • 15.5.7 Capability Overview
  • 15.5.8 Technology & Innovation Focus
  • 15.5.9 Customers / End Users
  • 15.5.10 Competitive Positioning
  • 15.5.11 Key Differentiators
  • 15.5.12 Portfolio Matrix
  • 15.5.13 SWOT Analysis
  • 15.5.14 Future Outlook
• 15.6 Thermo Fisher Scientific, Inc.
  • 15.6.1 Business Overview
  • 15.6.2 Key Information
  • 15.6.3 Company Focus
  • 15.6.4 Strategic Insights
  • 15.6.5 Strategy Deployed
  • 15.6.6 Product & Service Portfolio
  • 15.6.7 Capability Overview
  • 15.6.8 Technology & Innovation Focus
  • 15.6.9 Customers / End Users
  • 15.6.10 Competitive Positioning
  • 15.6.11 Key Differentiators
  • 15.6.12 Portfolio Matrix
  • 15.6.13 SWOT Analysis
  • 15.6.14 Future Outlook
• 15.7 HitGen Inc.
  • 15.7.1 Business Overview
  • 15.7.2 Key Information
  • 15.7.3 Company Focus
  • 15.7.4 Strategic Insights
  • 15.7.5 Strategy Deployed
  • 15.7.6 Product & Service Portfolio
  • 15.7.7 Capability Overview
  • 15.7.8 Technology & Innovation Focus
  • 15.7.9 Customers / End Users
  • 15.7.10 Competitive Positioning
  • 15.7.11 Key Differentiators
  • 15.7.12 Portfolio Matrix
  • 15.7.13 SWOT Analysis
  • 15.7.14 Future Outlook
• 15.8 Genedata AG
  • 15.8.1 Business Overview
  • 15.8.2 Key Information
  • 15.8.3 Company Focus
  • 15.8.4 Strategic Insights
  • 15.8.5 Strategy Deployed
  • 15.8.6 Product & Service Portfolio
  • 15.8.7 Capability Overview
  • 15.8.8 Technology & Innovation Focus
  • 15.8.9 Customers / End Users
  • 15.8.10 Competitive Positioning
  • 15.8.11 Key Differentiators
  • 15.8.12 Portfolio Matrix
  • 15.8.13 SWOT Analysis
  • 15.8.14 Future Outlook
• 15.9 Relay Therapeutics, Inc.
  • 15.9.1 Business Overview
  • 15.9.2 Key Information
  • 15.9.3 Company Focus
  • 15.9.4 Strategic Insights
  • 15.9.5 Strategy Deployed
  • 15.9.6 Product & Service Portfolio
  • 15.9.7 Capability Overview
  • 15.9.8 Technology & Innovation Focus
  • 15.9.9 Customers / End Users
  • 15.9.10 Competitive Positioning
  • 15.9.11 Key Differentiators
  • 15.9.12 Portfolio Matrix
  • 15.9.13 SWOT Analysis
  • 15.9.14 Future Outlook
• 15.10 Merck KGaA
  • 15.10.1 Business Overview
  • 15.10.2 Key Information
  • 15.10.3 Company Focus
  • 15.10.4 Strategic Insights
  • 15.10.5 Strategy Deployed
  • 15.10.6 Product & Service Portfolio
  • 15.10.7 Capability Overview
  • 15.10.8 Technology & Innovation Focus
  • 15.10.9 Customers / End Users
  • 15.10.10 Competitive Positioning
  • 15.10.11 Key Differentiators
  • 15.10.12 Portfolio Matrix
  • 15.10.13 SWOT Analysis
  • 15.10.14 Future Outlook

Chapter 16. Winning Imperatives of Drug Discovery Platforms Market